Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Fibrogen Inc CS (FGEN)

Fibrogen Inc CS (FGEN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,112,965
  • Shares Outstanding, K 87,250
  • Annual Sales, $ 212,960 K
  • Annual Income, $ -86,420 K
  • 60-Month Beta 1.84
  • Price/Sales 19.17
  • Price/Cash Flow N/A
  • Price/Book 6.63

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.39
  • Number of Estimates 5
  • High Estimate 0.03
  • Low Estimate -0.82
  • Prior Year 0.23
  • Growth Rate Est. (year over year) -269.57%

Price Performance

See More
Period Period Low Period High Performance
1-Month
32.33 +46.58%
on 11/12/19
48.44 -2.17%
on 11/08/19
+9.07 (+23.67%)
since 11/06/19
3-Month
32.33 +46.58%
on 11/12/19
48.44 -2.17%
on 11/08/19
+5.71 (+13.70%)
since 09/06/19
52-Week
32.33 +46.58%
on 11/12/19
61.23 -22.60%
on 02/28/19
+6.46 (+15.78%)
since 12/06/18

Most Recent Stories

More News
Fibrogen Inc Rises 6.45% on Heavy Volume: Watch For Potential Pullback

Fibrogen Inc (NASDAQ:FGEN) traded in a range yesterday that spanned from a low of $46.58 to a high of $47.19. Yesterday, the shares gained 6.5%, which took the trading range above the 3-day high of $45.00...

FGEN : 47.39 (+0.53%)
FibroGen Announces Roxadustat Inclusion in China's National Reimbursement Drug List

FibroGen, Inc. (NASDAQ: FGEN) today reported roxadustat has been included on the updated National Reimbursement Drug List (NRDL) released by China's National Healthcare Security Administration (NHSA)....

FGEN : 47.39 (+0.53%)
Fibrogen Inc Rises 6.47% on Heavy Volume: Watch For Potential Pullback

Fibrogen Inc (NASDAQ:FGEN) traded in a range yesterday that spanned from a low of $41.55 to a high of $44.20. Yesterday, the shares gained 6.5%, which took the trading range above the 3-day high of $41.00...

FGEN : 47.39 (+0.53%)
SmarTrend Watching for Potential Pullback in Shares of Fibrogen Inc After 1.19% Gain

Fibrogen Inc (NASDAQ:FGEN) traded in a range yesterday that spanned from a low of $36.46 to a high of $37.67. Yesterday, the shares gained 1.2%, which took the trading range above the 3-day high of $37.59...

FGEN : 47.39 (+0.53%)
Top 5 Companies in the Biotechnology Industry with the Best Relative Performance (NVTA , FGEN , INSM , ALKS , GBT )

We looked at the Biotechnology industry and measured relative performance to find the top stocks. Relative outperformance is a bullish sign of underlying fundamental and technical strength. We look at...

FGEN : 47.39 (+0.53%)
INSM : 23.10 (+2.35%)
NVTA : 17.69 (+3.75%)
FIBROGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating FibroGen, Inc. on Behalf of Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized shareholder law firm, is investigating potential claims against FibroGen, Inc. (NASDAQ: FGEN) on behalf of FibroGen stockholders. Our investigation...

FGEN : 47.39 (+0.53%)
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages FibroGen (FGEN) Investors to Contact Its Attorneys, Firm Investigating Possible Securities Fraud

Hagens Berman urges FibroGen, Inc. (NASDAQ: FGEN) investors who have suffered significant losses to submit their loss now to learn if they qualify to recover their investment losses. The firm is investigating...

FGEN : 47.39 (+0.53%)
Glancy Prongay & Murray LLP Announces Investigation on Behalf of FibroGen, Inc. Investors

Glancy Prongay & Murray LLP ("GPM") announces an investigation on behalf of FibroGen, Inc. ("FibroGen" or the "Company") (NASDAQ: FGEN) investors concerning the Company and its officers' possible violations...

FGEN : 47.39 (+0.53%)
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of FibroGen, Inc. Investors

Law Offices of Howard G. Smith announces an investigation on behalf of FibroGen, Inc. ("FibroGen" or the "Company") (NASDAQ: FGEN) investors concerning the Company and its officers' possible violations...

FGEN : 47.39 (+0.53%)
SmarTrend Watching for Potential Rebound in Shares of Fibrogen Inc After 3.97% Loss

Fibrogen Inc (NASDAQ:FGEN) traded in a range yesterday that spanned from a low of $34.14 to a high of $35.69. Yesterday, the shares fell 4.0%, which took the trading range below the 3-day low of $34.35...

FGEN : 47.39 (+0.53%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakening short term outlook on maintaining the current direction.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Trade FGEN with:

Business Summary

FibroGen, Inc. is a research-based biotechnology company. It is focused on the discovery, development, and commercialization of therapeutic agents for treatment of anemia, fibrosis, cancer, and other serious unmet medical needs. The Company develops Roxadustat that is in Phase III clinical development...

See More

Key Turning Points

2nd Resistance Point 48.55
1st Resistance Point 47.97
Last Price 47.39
1st Support Level 46.40
2nd Support Level 45.42

See More

52-Week High 61.23
Fibonacci 61.8% 50.19
Last Price 47.39
Fibonacci 50% 46.78
Fibonacci 38.2% 43.37
52-Week Low 32.33

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar